# Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments

Source: https://onco.cc/key-papers/paper-lutetium-177-vipivotide-tetrax-prostate-journal-2023/  
OnCo record `paper-lutetium-177-vipivotide-tetrax-prostate-journal-2023` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Review on Lutetium-177 vipivotide tetraxetan in Prostate cancer, in Journal not given (2023), one of the most cited Europe PMC records with Lutetium-177 vipivotide tetraxetan in its title.

## Summary

Europe PMC indexes no abstract for this record; the title is the only text available.

Indexed on Europe PMC as PubMed record 40209019. Its title names Lutetium-177 vipivotide tetraxetan and its text names Prostate cancer; PubMed types it as a review (Review). It was matched automatically to the idea "Alpha-emitting PSMA therapy at first metastatic diagnosis" and no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Journal not given
- Year: 2023
- Authors: Authors not listed
- What it means: One of the most cited reviews Europe PMC returns for Lutetium-177 vipivotide tetraxetan in Prostate cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
- Caveats: Matched by Lutetium-177 vipivotide tetraxetan in the title and Prostate cancer in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.; A review summarises other studies; the primary reports it cites are the evidence.

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/40209019/
- Europe PMC: https://europepmc.org/article/MED/40209019

## Connected records

- ideas: [Alpha-emitting PSMA therapy at first metastatic diagnosis](https://onco.cc/ideas/idea-alpha-first-mhspc/), [Total-body PET for personalised radioligand dosing](https://onco.cc/ideas/idea-total-body-pet-dosimetry/)

---
JSON: https://onco.cc/api/v1/entities/paper-lutetium-177-vipivotide-tetrax-prostate-journal-2023.json